Loading
A single protein predicts whether a tumour will respond to DNA-damaging drug payloads. Measuring it could stop patients receiving a second drug of the same kind that will not work.
SLFN11 expression predicts sensitivity to topoisomerase 1 inhibitors and platinum across preclinical models and some clinical series, and its loss is a recognised mechanism of payload resistance. With most current ADCs carrying topoisomerase 1 payloads, SLFN11 immunohistochemistry on a progression biopsy could distinguish antigen-driven from payload-driven failure and direct patients to a different payload class such as a tubulin inhibitor.
Shares Sequencing HER2 ADCs by payload after T-DXd, Payload-class switching as the rule for ADC sequencing, ADC sequencing, Acquired resistance to every therapy.
Shares ADC sequencing, Payload (ADC), Topoisomerase-I inhibitors (and ADC payloads), Antibody-drug conjugate (ADC).
Shares Payload (ADC), Topoisomerase-I inhibitors (and ADC payloads), Antibody-drug conjugate (ADC).
Shares ADC sequencing, Acquired resistance to every therapy.
Shares Payload-class switching as the rule for ADC sequencing, Acquired resistance to every therapy, Antibody-drug conjugate (ADC).
Shares Payload-class switching as the rule for ADC sequencing, ADC sequencing, Biomarkers are not validated or standardised, Topoisomerase-I inhibitors (and ADC payloads).
Shares Payload-class switching as the rule for ADC sequencing, ADC sequencing, Payload (ADC), Acquired resistance to every therapy.
Shares Payload-class switching as the rule for ADC sequencing, Acquired resistance to every therapy, Histopathology & immunohistochemistry, Antibody-drug conjugate (ADC).